Boxer Capital
Boxer Capital caters to public companies based in the biotechnology industry.
Business Model:
Revenue: $13.8M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Boxer Capital Information
Geographic Data
Address: Tavistock Group
City: Bahamas
State: other
Zip:
Country: BS
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
1,439,918Website Global Rank
18,571Website Monthly Traffic
Twitter Followers
Description
Tavistock is an investment firm, involved in direct and secondary indirect investments.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2019 | Revolution Medicines | Series C | 100M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 9/2018 | Atreca | Series C | 125M |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 2/2022 | Seismic Therapeutic | Series A | 0 |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 5/2021 | Flare Therapeutics | Series A | 82M |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 8/2015 | Telesta Therapeutics | Venture Round | 0 |
| 1/2019 | Sojournix | Series C | 44M |
| 5/2018 | CiVi Biopharma | Venture Round | 49M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 9/2019 | Passage Bio | Series B | 110M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2017 | GTx | Post-IPO Equity | 48.5M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 11/2022 | Lusaris Therapeutics | Series A | 0 |
| 6/2021 | Ajax Therapeutics | Venture Round | 0 |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 2/2021 | Shoreline Biosciences | Series A | 0 |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 3/2021 | Asher Bio | Series A | 0 |
| 1/2019 | Cabaletta Bio | Series B | 0 |
| 3/2022 | Incyclix Bio | Series B | 0 |
| 1/2020 | Tyra Biosciences | Series A | 50M |
| 6/2023 | ORIC Pharmaceuticals | Post-IPO Equity | 0 |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 8/2020 | Tango Therapeutics | Venture Round | 50M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 8/2020 | Connect Biopharmaceuticals | Series C | 115M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2015 | AveXis | Series D | 65M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 4/2021 | GH Research | Series B | 125M |
| 12/2020 | Vivace | Series C | 30M |
| 2/2015 | G1 Therapeutics | Series B | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 1/2019 | Attune Pharmaceuticals | Series B | 23M |
| 7/2020 | Encoded Therapeutics | Series D | 0 |
| 10/2020 | Cedilla Therapeutics | Series B | 57.6M |
| 5/2021 | Nuvalent | Series B | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 7/2020 | BioAtla | Series D | 0 |
| 4/2020 | Tango Therapeutics | Series B | 60M |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 3/2023 | Flare Therapeutics | Series B | 0 |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 1/2022 | Alterome Therapeutics | Series A | 0 |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 4/2021 | Boundless Bio | Series B | 105M |
| 11/2022 | Alterome Therapeutics | Series A | 0 |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 1/2017 | CiVi Biopharma | Series A | 40M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2018 | Milestone Pharmaceuticals | Series D | 80M |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 3/2022 | Incyclix Bio | Series B | 0 |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 2/2022 | Seismic Therapeutic | Series A | 0 |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 1/2022 | Alterome Therapeutics | Series A | 0 |
| 1/2022 | Third Harmonic Bio | Series B | 0 |
| 12/2021 | EQRx | Post-IPO Equity | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
